# Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children

> **NCT05116241** · PHASE2 · COMPLETED · sponsor: **ILiAD Biotechnologies** · enrollment: 368 (actual)

## Conditions studied

- Bordetella Pertussis, Whooping Cough

## Interventions

- **BIOLOGICAL:** BPZE1 pertussis vaccine and placebo
- **BIOLOGICAL:** BPZE1 pertussis vaccine and Boostrix
- **BIOLOGICAL:** Placebo and Boostrix

## Key facts

- **NCT ID:** NCT05116241
- **Lead sponsor:** ILiAD Biotechnologies
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-11
- **Primary completion:** 2024-05-15
- **Final completion:** 2024-05-15
- **Target enrollment:** 368 (ACTUAL)
- **Last updated:** 2025-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05116241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05116241, "Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05116241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*